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ABSTRACT
Introduction: Lung cancer survival remains poor in the western world due to late 
presentation in most cases, leading to difficulty of treatment in these advanced and 
metastatic patients. Therefore, the development of a robust biomarker for prognosis 
and to monitor treatment response and relapse would be of great benefit. The use 
of Alu repeats and DNA Integrity Index has been shown to hold both diagnostic and 
prognostic value, and as it is obtained from the plasma of patients, it can serve as a 
non-invasive tool for routine monitoring. This study evaluates the efficiency of this 
technique in malignant lung cancer patients.
Methods: Plasma samples were collected from 48 patients, consisting of 29 lung 
cancer patients and 19 non-cancer controls. Alu repeat ratio and confounders were 
measured.
Results: Observations showed a higher Alu repeat ratio amongst the cancer group 
compared to controls (p=0.035), mean Alu ratio 0.38 (range 0.01-0.93) and 0.22 
(0.007-0.44) respectively, ROC curve analysis AUC 0.61 (p=0.22). Analysis by staging 
was more promising, whereby a higher DNA Integrity Index was seen in advanced 
cases compared to both early stage and controls, p<0.0001; AUC: 0.92 (P=0.0002) and 
p=0.0006, AUC – 0.88 (p=0.0007) respectively, however no significant difference was 
observed in the early stage compared to controls. Short term survival data also showed 
a DNA Integrity Index of >0.5 to be associated with poorer overall survival p=0.03.
Conclusion: The results of this study show a potential use of Alu repeats ratios 
for prognostic purposes in the advanced setting for lung cancer patients.
INTRODUCTION
Lung cancer is still one of the biggest killers in the 
western world today, with incidence remaining high, and 
as many as 46,403 new cases reported in the UK in 2014 
alone [1, 2]. It has been reported that between 30-50% of 
non-small cell lung cancer patients (NSCLC) will undergo 
recurrence [3], and variable response rates to chemotherapy 
drugs have hindered survival rates. Routine biomarker 
monitoring post-surgery could be of significant prognostic 
value, informing of possible relapse sooner, thus allowing 
rapid treatment. In addition, identifying such a prognostic 
biomarker could allow finding patients who benefit from 
therapies (i.e. radiotherapy, chemotherapy) as a means of 
monitoring and predicting response. With the emergence of 
blood based biomarkers, this is now becoming a possibility.
Given the current challenges in isolation and 
characterisation of CTCs for diagnostic or prognostic 
purposes, analysis of DNA isolated from peripheral blood 
might shed a light to tumour activity. More specifically, a 
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portion of this DNA, known as cell-free DNA (cfDNA) 
circulating in plasma or serum can be derived from normal 
cells, including normal apoptotic white blood cells as well 
as cancer cells.
Circulating tumour DNA (ctDNA) is the portion 
of circulating free DNA specifically derived from cancer 
cells [4, 5]. Typically in healthy individuals apoptosis of 
cells occurs naturally, and DNA is released and uniformly 
truncated in small fragments of 185-200 bp [6]. However, 
tumour necrosis generates a spectrum of DNA fragments 
with different strand lengths typically >200bp, due to the 
pathological process of cell death consisting not only 
of apoptosis but also necrosis, autophagy and mitotic 
catastrophe [7]. Ineffective deoxyribonuclease activity is 
also reported to contribute to longer DNA fragments due 
to incomplete digestion of genomic DNA [8].
In addition to its potential role as a detection and 
prognostic method, ctDNA was also evaluated as a way 
of monitoring tumour progression and testing whether 
a patient’s tumour would respond to targeted drug 
treatments. The percentage of ctDNA originating from 
tumour cells however, has been estimated to range from 
10% to 90% of the total cell free DNA population, its 
applicability as a plasma biomarker may therefore depends 
on the type of disease [9].
Classified as Short Interspersed Elements (SINE), 
Alu is the most abundant mobile element in the human 
genome [10]. A full length can span approximately 
300 base pairs (bp) in length, and include two tandem 
monomer units, separated by a poly “A” stretch [10]. 
Studies have shown the Alu-repeat measurements to 
adequately predict the disease in cases of colorectal, 
ovarian, breast and lung cancers, however use of Alu 
repeats was shown to be ineffective in pancreatic cancer 
[6-8, 11, 12].
To test this hypothesis in lung cancers, we 
conducted a case control study to measure using a real-
time PCR-based assay, the Alu repeats in a total of 48 
plasma samples. For this study we have used two distinct 
set of primers: One set of primers amplified shorter DNA 
fragments (115 bp in length; reflecting the total cfDNA); 
whereas the second primer set amplified only the longer 
DNA fragments (247 bp; representing the amount of DNA 
released from cancerous cells). DNA integrity index was 
calculated as the ratio of qPCR results with the 2 primer 
sets: Alu247/Alu115. Detection of these longer ctDNA 
fragments and quantification of their relative abundance 
in plasma compared to short cfDNA fragments, calculating 
a DNA Integrity Index has already been explored with 
promising results [13, 14].
To summarise, this study evaluates the use of Alu 
repeat and DNA integrity Index in lung cancer patients, and 
its ability to diagnose lung cancer in both early and advanced 
stages. The study wishes to assess whether a higher DNA 
integrity index is associated with more advanced lung cancer, 
hence allowing differential staging and prognostic prediction 
of patients based on their Alu repeat ratio.
RESULTS
DNA integrity index is of prognostic rather 
diagnostic value
Plasma samples were collected and processed from 
48 participants (Table 1), and extracted DNA processed by 
qPCR for Alu 115 and Alu 247. Data obtained from qPCR 
was analysed, and RQ values and DNA Integrity Index 
calculated and plotted (Figure 1). DNA Integrity Index 
is given as a value between 0-1 (raw data available in 
supplementary Table 1), with 1 indicating higher ratio of 
Figure 1: Scatter plot showing DNA integrity index. (A) – shows a higher DNA Integrity Index in lung cancer compared to 
controls, p=0.035. (B) – shows an increased DNA Integrity Index in the advanced cancer group (III-IV including metastatic) compared to 
both early stage (I-II) and controls, p<0.0001 and p= 0.0006 respectively. Statistical significance was not achieved in the early stage vs 
control groups.
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Alu 247, hence increased circulating tumour DNA burden 
[6, 7].
A higher DNA Integrity Index is seen in the lung 
cancer group compared to controls, p=0.035. (Figure 
1A). Comparison of the DNA Integrity Index in advanced 
cancer cases to both controls and early stage cancers are 
shown to be significantly higher, p=0.0006 and p<0.0001 
respectively (Figure 1B).
Using a one-way ANOVA, comparing control, early 
and late cancer had a significant overall effect on Alu 
levels (F(2,45) = 26.00, p < 0.001). Following this, we 
conducted a contrast analysis and found that, both disease 
groups had significantly higher Alu levels than controls 
(t(45) = 3.46, p = 0.001). Controls had significantly lower 
Alu than late group patients (t(45) = 6.20, p < 0.001). 
Controls and early cancer groups were not different on Alu 
levels (t(45) = 0.69, p > 0.05), 4. Late group patients had 
significantly higher Alu levels than early group patients 
(t(45) = 6.67, p < 0.001).
We expanded on these observations by calculating 
sensitivity and specificity data; obtained by receiver 
operative characteristics (ROC) curves, and calculation 
of area under the curve (AUC), using 95% confidence 
intervals (Figure 2). There was strong sensitivity and 
specificity in advanced cases to early, and advanced cases 
to controls, AUC – 0.92, p=0.0002 and AUC – 0.88, 
p=0.0077 respectively. Poorer sensitivity and specificity 
results were seen in the all lung cancer vs controls and 
early vs controls, AUC – 0.61, p=0.22 and AUC – 0.67, 
p=0.12 respectively.
Collectively these data, demonstrate that DNA 
integrity index is only useful when late stage is compared 
to early one, thus demonstrating a potential use of this test 
for prognostic purposes.
DNA integrity index can determine survival
On comparison of pathology and staging, similar 
mean DNA Integrity Index were calculated in the early 
stage primary lung cancer group and controls, with 
considerable overlap as shown by the range 0.18 (0.01-
0.44) and 0.22 (0.007-0.44) respectively. Notably higher 
DNA Integrity Indexes are seen in the late stage and 
metastatic groups, 0.61 (0.04-0.91) and 0.58 (0.17-0.9). 
Little difference is observed in median survival (survival 
in days from surgery), where in early stage median 
survival is calculated at 434 days post operation, this is 
slightly higher in the metastatic group at 454 days and 460 
days in the late stage group (Table 2). Median survival 
data using the 0.5 index, showed a median survival in 
days in the <0.5 and >0.5 group of, 434 and 457 days post 
operatively.
Overall survival analysis by Kaplan Meier (estimates 
survival function, and proportion of patients alive over 
time) of the DNA Integrity Index, using the 0.5 index as a 
guide for high and low levels, showed significantly poorer 
overall survival in the patients with a DNA Integrity Index 
of >0.5, p=0.03 (Figure 3). Demonstrating the prognostic 
value of DNA integrity measurements in advanced lung 
cancer cases.
Sexual dimorphism and DNA integrity index
We further interrogated the data, using known 
factors for lung cancer that can influence survival. No 
significant correlations were found between Alu and CT 
tumour size (r = 0.21, p > 0.05; Supplementary Figure 
1). Alu was also unrelated to age, smoking or diabetes 
mellitus (all p > 0.05). The only background variable 
associated with Alu was gender: women had significantly 
higher Alu (0.40) than men (0.15; t (27.33) = 4.09, p 
< 0.001. Subsequently, we found that the main group 
effect on Alu remained significant also after statistically 
controlling for gender (F(2,38) = 16.52, p < 0.001).
DISCUSSION
Liquid biopsies are an attractive and more practical 
alternative for routine cancer monitoring, in contrast to 
current surgical biopsies. With ctDNA readily available 
in the plasma of cancer patients, various efforts have been 
made to exploit their clinical utility, one of which being 
the DNA Integrity Index [6, 8, 15]. This study evaluates 
the efficacy of the DNA Integrity Index, by means of Alu 
repeat analysis of ctDNA found in the plasma of patients 
with malignant lung tumours.
Based on the premise that tumour cells undergo 
more chaotic cell death compared to mostly apoptosis 
in normal cells, we would expect to find a higher ratio 
of fragmented DNA in the cancer cohort. As the disease 
progresses one would expect an increased DNA Integrity 
Index to reflect the increased tumour burden and thus 
shedding of fragmented DNA, potentially providing a 
means not only to identify and diagnose cancer patients, 
but also differentiate based on staging and advancement of 
disease. Umetami et al (2006) demonstrated a significantly 
increased DNA Integrity Index, even in patients with 
localised disease for colorectal cancer, demonstrating its 
utility as a diagnostic tool [6]. More recently, a study in 
95 breast cancer patients, revealed a significantly higher 
DNA Integrity Index, compared to benign and control 
samples (p<0.001). The group also reported sensitivity 
and specificity values of 85 and 100%, respectively, 
concluding the clinical utility of ctDNA, and correlation 
with TNM staging [16].
The results of this study show an increased DNA 
Integrity Index in the cancer cohort (average ratio: 0.38 
(range 0.01-0.93) compared to controls (average ratio: 
0.22 (0.007-0.44), p= 0.035. ROC curve (Figure 2A) 
analysis however indicates poor sensitivity and specificity. 
Furthermore, there is considerable overlap between the 
cancer and non-cancer cohort, which can also be seen 
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Figure 2: ROC curve analysis of diagnostic sensitivity and specificity of using ALU repeat ratios. (A) – all lung cancer vs 
controls, AUC – 0.61, p = 0.22; (B) – advanced cases vs controls, AUC – 0.88, p=0.0077; (C) – Early stage vs controls, AUC 0.67, P=0.23; 
(D) – advanced cases vs early stage, AUC – 0.92, P=0.0002.
Table 1: Clinical details of recruited patients
Variable Value Percent (%)
Total 48 100%
Mean age (±SD) 60±15 -
Males/Females 25/23 52.1/47.9
Pathology
All cancer 29 60.4
 Primary lung cancer 22 75.9
  Adenocarcinoma 15 68.2
  Squamous cell carcinoma 7 31.8
 Metastatic Cancer 7 24.1
 Non-cancer control 19a 40
Stagingb
 I-II 17 77.2
 III-IV 5 22.7
a Non- cancer controls include 2 patients awaiting bullectomy surgery.
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in similar studies [6, 7]. No normal established baseline 
exists, healthy non-cancer patients will be expected 
to show both shorter and larger DNA fragments due to 
biological cell death processes. Inflammation and auto 
immune diseases are contributing factors to cell death 
rates, explaining higher DNA Integrity Index values in 
non-cancerous controls, with the lower ratio’s seen in the 
cancer group attributed to effective DNA clearance, as well 
as minimal cell death [17]. Other factors such as trauma, 
stroke can also effect the Alu ratio, hence limiting the 
value for cancer [18-23]. This overlap between the cancer 
and non-cancer group, is suggestive of poor specificity 
and thus questioning its potential as a diagnostic tool.
However, when cancer patients are stratified by 
cancer stage (according to TNM staging system, as 
seen in Figure 1B, a significantly higher DNA Integrity 
Index is observed in the advanced patients (III-IV and 
metastatic), compared to both the early stage (p<0.0001) 
and normal cohort (p=0.0006). Moreover, ROC curve 
analysis demonstrates a high diagnostic accuracy between 
advanced cases and early stage and advanced cases and 
controls. The results of this study are generally in line 
with recent studies [6, 7], and suggests a prognostic role 
for this biomarker in advanced cancers. Literature also 
suggests that DNA released from malignant tumours into 
the bloodstream is enhanced by lymphovascular invasion, 
as direct lymphatic or blood flow through the tumours 
enables dissemination of viable tumour cells, and thus 
can enhance the diffusion of DNA released from dead 
tumour cells into the bloodstream. As a result, circulating 
DNA may be directly related to tumour progression and 
rate of tumour cell turnover, representing biologic tumour 
aggressiveness [7], which would agree with the results of 
this study.
Analysis of DNA Integrity Index against staging 
showed Alu repeat ratios of >0.5 in the advanced and 
Table 2: DNA integrity index by staging, including median survival times, show advanced cases and metastatic patients to 
have a higher Alu repeat ratios, compared to early stage and non-cancer controls, 0.86, 0.51, 0.18, and 0.22 respectively
Pathology Patients (n) Mean DNA Integrity Index (Range) Median survival
Primary lung cancer:
 Early stage (I-II) 17 0.18 (0.01-0.44) 434
 Late stage (III-IV) 5 0.86 (0.71-0.93) 460
Metastatic 7 0.51 (0.12-0.93) 454
Non cancer controls 19 0.22 (0.007-0.44) -
Median survival times however do not seem to be significantly influenced by a higher DNA Integrity Index.
Figure 3: Kaplan Meier plot of overall survival in lung cancer patients based on DNA integrity index, patients with Alu 
reading >0.5 show poorer survival, p=0.03.
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metastatic patients (Table 2) when compared to controls 
and early stage. Supporting the notion that with disease 
progression more tumour DNA is shed into the circulation. 
Short term follow up data was also acquired, and overall 
survival plotted by DNA Integrity Index, whereby patients 
were divided by a ratio of either <0.5 or >0.5, based on 
the statistical data generated (Table 2). Furthermore, 
with the DNA Integrity Index falling between 0 and 1, 
the middle point of 0.5 was assumed a sensible cut off to 
distinguish higher ratios from lower. A similar approach 
and cut-off was also utilised in a recent study in breast 
cancers [16]. Overall survival was seen to be significantly 
worse in the >0.5 DNA Integrity Index cohort (p=0.03)., 
suggesting a direct association between the DNA Integrity 
Index and poorer prognosis, similar observations in overall 
survival were reported by Basnet et al (2016) in colorectal 
patients [24]. Moreover, the patients with a DNA Integrity 
Index of >0.5 were more advanced and metastatic cases, 
where a higher ctDNA content would be expected with 
cancer growth and spread, along with a poorer prognosis. 
Furthermore, these results suggest the utility of the DNA 
Integrity Index in predicting prognosis and OS.
Little difference was observed in the median 
survival in day’s data, there was also no correlation seen 
between tumour mass and DNA Integrity Index, however 
one must consider the small number of advanced and 
metastatic patients.
Interestingly, ANOVA analysis revealed that women 
had significantly higher DNA Integrity Index (0.40) than 
men (0.15), p < 0.001. Subsequently, we found that the 
main group effect on the Alu ratio remained significant 
also after statistically controlling for gender (F(2,38) 
= 16.52, p < 0.001). This could be explained by sexual 
dimorphisms in DNA, in relation to DNA methylation and 
Alu repeats [25, 26].
Findings from our study are in line with similar 
studies, including Wang et al, (2003) who reported a 
significant increase in the DNA Integrity Index in ovarian 
and gynaecological cancers, concluding its clinical utility. 
Similarly studies in colorectal, periampullary, breast, 
ovarian, head and neck and prostate cancers [6-8, 27-29] 
also report positive results for the use of Alu repeats both 
diagnostically and prognostically. In contrast studies in 
pancreatic, gastrointestinal, colorectal cancer [30, 31] have 
concluded against their utility as a clinical tool due to poor 
sensitivity and specificity. The results from our findings 
support the latter, despite some promising results there is a 
lack of sensitivity and specificity in this method, highlighted 
by the overlap seen between the control and cancer cohorts. 
A larger sample size may alleviate some limitations from 
this study, however the DNA Integrity Index lacks value 
as a diagnostic tool, and requires improvements and 
standardisation of process. Positive results were obtained in 
the advanced stages, suggesting a potential role in patient 
staging, disease monitoring and prognosis.
MATERIALS AND METHODS
In total 48 individuals were recruited to the study, 
including 29 lung cancer patients awaiting resection of 
their known primary or secondary lung cancer (Table 
1). Samples were also taken from 17 healthy volunteers 
(males and females), and 2 patients undergoing non-cancer 
lung surgery. Prior consent was sought from patients 
following ethical approval from NRES (ref 14/LO/1284).
Ten ml blood samples were collected from patients 
into EDTA tubes, and centrifuged for 10 mins at 2500RPM. 
Two ml of the plasma layer was removed careful not to 
disturb the red blood cell sediment, the plasma was spun 
again for purity for a further 5 mins at 2500 RPM, and 
plasma extracted and stored at -80°C until further use. DNA 
extraction was carried out using the QIAmp DNA mini 
kit (QIAGEN, Germany) as per manufacturer’s protocol. 
Extracted DNA was measured and stored at -20°C.
DNA samples were processed by quantitative 
PCR (qPCR) on the Quantistudio 7 (ABI), using SYBR 
green mastermix (ABI). Primer sequences were taken 
from Umetani et al. (2006), and obtained from Sigma, 
with the following sequence’s Alu 115 forward: - 
5’-CCTGAGGTCAGGAGTTCGAG-3’; reverse, 5’-CCCGA 
GTAGCTGGGATTACA-3’; Alu247 primers: forward, 
5’-GTGGCTCACGCCTGTAATC-3’; reverse, 5’-CAGG 
CTGGAGTGCAGTGG-3’.
Relative quantification (RQ) was calculated for each 
sample, and DNA Integrity Index calculated as follows: 
RQ Alu 247/RQ Alu 115 [6].
Statistical analysis, all data’s were analysed using 
the GraphPad Prism version 5. An F-test was performed 
to assess the variance s, and two-tailed unpaired Student’s 
t-tests with Welch’s correction for unequal variance were 
performed to assess significance. Receiver operating 
characteristics (ROC) curve and area under the curve 
(AUC) analysis were used to assess diagnostic utility. 
Survival data was calculated using Kaplan Meier plots. 
All statistics calculated with a 95% confidence interval.
Abbreviations
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characteristics (ROC), area under the curve (AUC).
Author contributions
 Dimple Chudasama – Sample collection/processing, 
experimentations, analyses and writing of manuscript
Zeynep Aladag – Experimentation contribution
Mayla I Felicien – Experimentation contribution
 Marcia Hall – Funding and provision of clinical 
samples
Oncotarget21287www.oncotarget.com
 Julie Beeson – collection and interpretation of 
outcomes data
 Nizar Asadi – collection and interpretation and 
analyses of outcomes data
 Yori Gidron – statistical analysis and editing of 
paper
 Emmanouil Karteris – co-PI for project, 
interpretation of data and writing manuscript
 Vladimir B Anikin – PI for project, data 
interpretation and wiring of manuscript.
 ACKNOWLEDGMENTS AND FUNDING
EK and VA should be considered joint last co-
authors as they have contributed equally to the manuscript. 
Study funded by Cancer Treatment Research Trust 
(CTRT).
CONFLICTS OF INTEREST
The authors have no conflicts of interest to 
declare.
REFERENCES
1. Lung cancer statistics. British Lung Foundation. [cited 2017 
Sep 22], from https://statistics.blf.org.uk/lung-cancer.
2. Lung cancer incidence statistics. Cancer Research UK [cited 
2017 May 8], from http://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/
lung-cancer/incidence#heading-Three.
3. Uramoto H, Tanaka F. Recurrence after surgery in patients 
with NSCLC. Transl lung cancer Res. AME Publications. 
2014; 3:242–9.
4. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova 
OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP. 
Cell-free and cell-bound circulating DNA in breast tumours: 
DNA quantification and analysis of tumour-related gene 
methylation. Br J Cancer. 2006; 94:1492–5.
5. Kidess E, Jeffrey SS. Circulating tumor cells versus tumor-
derived cell-free DNA: rivals or partners in cancer care in the 
era of single-cell analysis? Genome Med. 2013; 5:70.
6. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, 
Bilchik AJ, Hoon DS. Increased integrity of free circulating 
DNA in sera of patients with colorectal or periampullary 
cancer: direct quantitative PCR for ALU repeats. Clin Chem. 
2006; 52:1062–9.
7. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, 
Nakagawa T, Martino S, Hoon DS. Prediction of Breast 
Tumor Progression by Integrity of Free Circulating DNA in 
Serum. J Clin Oncol. 2006; 24:4270–6.
8. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei 
K, Cheng CC, Roden R, Sokoll LJ, Chan DW, Shih IM. 
Increased plasma DNA integrity in cancer patients. Cancer 
Res. 2003; 63:3966–8.
9. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, 
Hesch RD, Knippers R. DNA fragments in the blood plasma 
of cancer patients: quantitations and evidence for their 
origin from apoptotic and necrotic cells. Cancer Res. 2001; 
61:1659–65.
10. Zhang W, Edwards A, Fan W, Deininger P, Zhang K. Alu 
distribution and mutation types of cancer genes. BMC 
Genomics. 2011; 12:157.
11. Sikora K, Bedin C, Vicentini C, Malpeli G, D’Angelo 
E, Sperandio N, Lawlor RT, Bassi C, Tortora G, Nitti D, 
Agostini M, Fassan M, Scarpa A. Evaluation of cell-free 
DNA as a biomarker for pancreatic malignancies. Int J Biol 
Markers. 2015; 30:136-41.
12. Sriram KB, Relan V, Clarke BE, Duhig EE, Windsor MN, 
Matar KS, Naidoo R, Passmore L, McCaul E, Courtney D, 
Yang IA, Bowman RV, Fong KM. Pleural fluid cell-free DNA 
integrity index to identify cytologically negative malignant 
pleural effusions including mesotheliomas. BMC Cancer. 
2012; 12: 428.
13. Agostini M, Enzo MV, Bedin C, Belardinelli V, Goldin E, 
Del Bianco P, Maschietto E, D’Angelo E, Izzi L, Saccani A, 
Zavagno G, Nitti D. Circulating cell-free DNA: a promising 
marker of regional lymphonode metastasis in breast cancer 
patients. Cancer Biomark. 2012; 11:89–98.
14. da Silva Filho BF, Gurgel AP, Neto MÁ, de Azevedo DA, de 
Freitas AC, Silva Neto Jda C, Silva LA. Circulating cell-free 
DNA in serum as a biomarker of colorectal cancer. J Clin 
Pathol. 2013; 66: 775–8.
15. Volinia S, Mascellani N, Marchesini J, Veronese A, 
Ormondroyd E, Alder H, Palatini J, Negrini M, Croce CM, 
Batzer M. Genome Wide Identification of Recessive Cancer 
Genes by Combinatorial Mutation Analysis. PLoS One. 
2008; 3:3380.
16. Kamel AM, Teama S, Fawzy A, El Deftar M. Plasma DNA 
integrity index as a potential molecular diagnostic marker for 
breast cancer. Tumour Biol. 2016; 37: 7565–72.
17. Holdenrieder S, Burges A, Reich O, Spelsberg FW, Stieber 
P. DNA integrity in plasma and serum of patients with 
malignant and benign diseases. Ann N Y Acad Sci. 2008; 
1137: 162–70.
18. Chiu TW, Young R, Chan LYS, Burd A, Lo DY. Plasma 
cell-free DNA as an indicator of severity of injury in burn 
patients. Clin Chem Lab Med. 2006; 44: 13–7.
19. Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, 
Groeneveld AB, Caliezi C, van Nieuwenhuijze AE, van 
Mierlo GJ, Eerenberg AJ, Lämmle B, Hack CE. Elevated 
nucleosome levels in systemic inflammation and sepsis. Crit 
Care Med. 2003; 31:1947–51.
20. Lam NY, Rainer TH, Chan LY, Joynt GM, Lo YM. Time 
course of early and late changes in plasma DNA in trauma 
patients. Clin Chem. 2003; 49: 1286–91.
Oncotarget21288www.oncotarget.com
21. Lam NY, Rainer TH, Wong LK, Lam W, Lo YM. Plasma 
DNA as a prognostic marker for stroke patients with negative 
neuroimaging within the first 24h of symptom onset. 
Resuscitation. 2006; 68:71–8.
22. Rainer TH, Lam NY, Man CY, Chiu RW, Woo KS, Lo YM. 
Plasma β-globin DNA as a prognostic marker in chest pain 
patients. Clin Chim Acta. 2006; 368:110–3.
23. Holdenrieder S, Eichhorn P, Beuers U, Samtleben W, 
Schoenermarck U, Zachoval R, Nagel D, Stieber P. 
Nucleosomal DNA Fragments in Autoimmune Diseases. Ann 
N Y Acad Sci. 2006; 1075:318–27.
24. Basnet S, Zhang ZY, Liao WQ, Li SH, Li PS, Ge HY. The 
Prognostic Value of Circulating Cell-Free DNA in Colorectal 
Cancer: A Meta-Analysis. J Cancer. 2016; 7: 1105–13.
25. El-Maarri O, Becker T, Junen J, Manzoor SS, Diaz-
Lacava A, Schwaab R, Wienker T, Oldenburg J. Gender 
specific differences in levels of DNA methylation at 
selected loci from human total blood: a tendency toward 
higher methylation levels in males. Hum Genet. 2007; 
122:505–14.
26. Webster MT, Smith NG, Hultin-Rosenberg L, Arndt PF, 
Ellegren H. Male-driven biased gene conversion governs the 
evolution of base composition in human alu repeats. Mol Biol 
Evol. 2005; 22:1468–74.
27. Lehner J, Stötzer OJ, Fersching DM, Nagel D, Holdenrieder 
S. Plasma DNA integrity indicates response to neoadjuvant 
chemotherapy in patients with locally confined breast cancer. 
Int J Clin Pharmacol Ther. 2013; 51:59–62.
28. Jiang WW, Zahurak M, Goldenberg D, Milman Y, Park HL, 
Westra WH, Koch W, Sidransky D, Califano J. Increased 
plasma DNA integrity index in head and neck cancer patients. 
Int J Cancer. 2006; 119:2673–6.
29. Hanley R, Rieger-Christ KM, Canes D, Emara NR, Shuber AP, 
Boynton KA, Libertino JA, Summerhayes IC. DNA integrity 
assay: a plasma-based screening tool for the detection of 
prostate cancer. Clin Cancer Res. 2006; 12:4569–74.
30. Utomo WK, Janmaat VT, Verhaar AP, Cros J, Lévy P, 
Ruszniewski P, den Berg MS, Jenster G, Bruno MJ, Braat H, 
Fuhler GM, Peppelenbosch MP. DNA integrity as biomarker 
in pancreatic cyst fluid. Am J Cancer Res. 2016; 6:1837–41.
31. Boddy JL, Gal S, Malone PR, Shaida N, Wainscoat JS, 
Harris AL. The role of cell-free DNA size distribution in the 
management of prostate cancer. Oncol Res. 2006; 16:35–41. 
